High intra-tumoral and serum matrix metalloproteinase 9 levels are associated with reduced survival of patients with glioblastoma and brain metastases
This study shows that high intra-tumoral and/or sera MMP-9 levels at diagnosis are linked to significantly worse patient OS. Additionally, intra-tumoral and sera MMP-9 may help identify glioblastoma and BM recurrence or progression. Importantly, sera MMP-9 levels can be monitored over time non-invasively, and an increase might indicate tumor progression.
Authors
- Victor Dyomin (ORCID: https://orcid.org/0000-0002-1249-1922)
- Moumita Chakraborty (ORCID: https://orcid.org/0000-0001-7509-1777)
- I Melamed
- Michal Hershfinkel (ORCID: https://orcid.org/0000-0003-1652-1989)
- Tali Zamed
- Yarden Kezerle (ORCID: https://orcid.org/0000-0003-0132-7454)
- Hila Asraf (ORCID: https://orcid.org/0000-0003-4134-1218)
- Adi Alt
- Konstantin Lavrenkov
- Vladimir Merkin
- Tehila Kaisman‐Elbaz (ORCID: https://orcid.org/0000-0002-0658-9624)
- Yael Eskira
- Romi Bari
- Sivan Turiel
- Guy Dumanis
- Noa Rotem-Dai
- Snir Haddad-Shlaifshtein
- Maya Atar-Vardi
- Ronit Razon
Institutions
- Ben-Gurion University of the Negev (IL)
- Soroka Medical Center (IL)
- Ariel University (IL)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fonc.2025.1577492
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00